Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-13
2011-11-01
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S274000
Reexamination Certificate
active
08048888
ABSTRACT:
The present invention describes a method or uses of prevention and/or treatment of a cancer or a tumor, and in particular to a combination therapy, methods, compositions and pharmaceutical packages comprising an inhibitor of receptors of the EGFR family or a chemotherapeutically active pyrimidine analogue and certain platinum-based chemotherapeutic agents.
REFERENCES:
patent: 2006/0019268 (2006-01-01), Cheng et al.
patent: 2006/0069101 (2006-03-01), Kim et al.
patent: WO 2004/096224 (2004-11-01), None
patent: WO 2005/095651 (2005-10-01), None
Kelland L.R. (Overcoming Resistance to Platinum Therapy in Patients with Advanced Cancer, Am J Cancer 2002: 1 (4): 247-255).
Belliere et al.,Oncologie,4(6): 368-372 (2002) (not enclosed herewith).
Cunningham et al.,Cancer Treatment Reviews,27(4): 211-220 (2001).
Demario et al.,Journal of Clinical Oncology,16(7): 2562 (1998).
Deutsche Apotheker Zeitung,143(39): 35-36 (2003).
Faivre et al.,Bulletin Du Cancer,86(10): 861-865 (1999).
Hinerman et al.,Therapy, Future Drugs,1(1): 67-74 (2004) (Abstract only).
Kelland, L.R.,American Journal of Cancer,1(4): 247-255 (2002).
Kweekel et al.,Cancer Treatment Reviews,31(2): 90-105 (2005).
Pe{hacek over (s)}ek et al.,Studia Pneumologica Et Phthiseologica,59(1): 14-18 (1999).
Smith, D.C.,Urologic Clinics of North America,26(2): 323-331 (1999).
Stokes et al.,Gynecologic Oncology,97(3): 790-795 (2005).
Zelek et al.,Journal of Clinical Oncology,20(10): 2551-2552 (2002).
Calabresi et al., Section IX Chemotherapy of Neoplastic Diseases—Introduction, Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed., (J. Hardman, L. Limbird, and A. Gilman eds.), (McGraw-Hill, New York, 2001) (pp. 1381, 1383-1385 and 1388 provided).
Fokkema et al., “JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin”, Biochemical Pharmacology, 63: 1989-1996 (2002).
Gura, T., “Systems for Identifying New Drugs Are Often Faulty”, Science, 278(5340): 1041-1042 (1997).
Kelland, L.R., “An update on satraplatin: the first orally available platinum anticancer drug”, Exp. Opin. Invest. Drugs, 9 (6): 1373-1382 (2000).
Petrylak, D.P., “Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer”, Reviews in Urology, 5(Suppl. 2): S14-S21 (2003).
Vogelstein et al., Chapter 1, in the Genetic Basis of Human Cancer 2nd ed., (B. Vogelstein and K. Kinzler eds.), (McGraw-Hill, 2002) p. 3.
Ivanov Igor
Obermayr Franz
Schaab Christoph
Schuhmacher Marino
Wosikowski-Buters Katja
Agennix AG
Betton Timothy E
O'Brien David G.
Padmanabhan Sreeni
Yankwich Leon R.
LandOfFree
Anti-proliferative combination therapy using certain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-proliferative combination therapy using certain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-proliferative combination therapy using certain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286562